Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELD-ATG dose-finding trial in newly diagnosed type 1 diabetes
ISRCTN15367345Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of antithymocyte globulin in diabetes mellitus type 1 (T1D) (3 arms), sponsored by UZ Leuven. Primary endpoint: Primary efficacy endpoint. Started Feb 2021; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN15367345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15367345.